Peritoneal Surface Malignancies
Yusuf Ciftci, BS
Medical Student
Johns Hopkins University School of Medicine
Baltimore, Maryland, United States
Yusuf Ciftci, BS
Medical Student
Johns Hopkins University School of Medicine
Baltimore, Maryland, United States
Yusuf Ciftci, BS
Medical Student
Johns Hopkins University School of Medicine
Baltimore, Maryland, United States
Shannon N. Radomski, MD (she/her/hers)
Resident Physician
Johns Hopkins University School of Medicine
Baltimore, Maryland, United States
Blake Johnson, BS
Medical Student
Johns Hopkins University School of Medicine, United States
Fabian M. Johnston, MD, MHS
Associate Professor of Surgery
Division of Gastrointestinal Surgical Oncology, Johns Hopkins University School of Medicine, Baltimore, MD, United States
Baltimore, Maryland, United States
Jonathan B. Greer, MD
Assistant Professor of Surgery
Johns Hopkins University School of Medicine, United States
Cytoreductive surgery with hyperthermic intraperitoneal chemotherapy (CRS-HIPEC) is an increasingly utilized, but costly, treatment option for select patients with peritoneal malignancies. Higher surgeon and institutional volume have both been shown to improve outcomes and reduce costs in other oncological procedures. The impact of institutional volume and progress along an institutional learning curve on the cost of CRS-HIPEC is unknown.
Methods:
We performed a retrospective cohort study of patients undergoing CRS-HIPEC from 2016-2022 at a single quaternary center. Our study cohort was divided into 4 equally sized volume quartiles based on date of surgery. We utilized cumulative sum plots and split-group analysis to characterize the institutional learning curve based on operating room cost, operative time, length of stay (LOS), and overall and serious morbidity. Bivariate analysis was performed using a Kruskal-Wallis test to compare continuous variables and a χ2 test to compare categorical variables.
Results:
Of 201 included patients, median age (IQR) was 57 (47-65) years; 113 (56%) patients were female; 143 (71%) were white; and 107 (53%) had private insurance. Age, sex, race, and primary tumor location did not differ between volume quartiles. Median operating room cost of CRS-HIPEC varied between volume quartiles with the highest meidan cost in quartile C ($42,639 [IQR: $32,477-$54,872], followed by quartile D ($38,246 [$31,864-$42,298], quartile B ($36,232 [$27,635-$42,312]), and lastly quartile A $26,652 [IQR: $23,174-$33,299] (p< 0.001). Operative time, LOS, ICU LOS, and overall and serious morbidity followed a similar trend as cost with an initial increase followed by stabilization and decrease over time. We found that the learning curve is triphasic; with an initial stabilization in the cost of CRS-HIPEC at 86 cases, followed by stabilization in operative time and LOS at 103 and 96 cases, and finally a stabilization in the rate of overall and serious complications after 150 cases (Figure 1).
Conclusions:
Cost, operative time, length of stay, and complications initially increased then stabilized and decreased as institutional volume increased over a period of 6 years. The CRS-HIPEC learning curve is triphasic, with cost stability achieved relatively early compared to other markers of surgical proficiency.